Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma

Cancer
Thomas YauRonnie T P Poon

Abstract

This phase 1-2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor-PTK787/ZK222584 (PTK)-in combination with intravenous doxorubicin for the treatment of advanced hepatocellular carcinoma (HCC) patients. In phase 1, advanced HCC patients received PTK at escalating doses together with doxorubicin 60 mg/m2 given as an intravenous bolus every 3 weeks to establish the maximum tolerated dose (MTD). Subsequently, in phase 2, all patients received the same regimen with oral PTK at the MTD dose every 3 weeks for a maximum of 6 cycles. Nine patients were recruited in phase 1, with the MTD established as 750 mg daily. Overall, 27 patients received the regimen with PTK at 750 mg daily. The median age was 52 years (range, 23-73 years), and 63 percent of patients were chronic hepatitis B carriers. Notably, the majority of patients had Child-Pugh B cirrhosis. The overall response rate was 26.0%, with all the responding patients having partial response. Another 20% of patients achieved stable disease for at least 12 weeks. The median progression-free survival was 5.4 months (range, 0.27-23.6 months), and overall survival was 7.3 months (range, 0.8-23.6 months). The commonest grade 3 or 4 nonhematological toxicities ...Continue Reading

References

Mar 14, 1996·The New England Journal of Medicine·V MazzaferroL Gennari
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·D M ParkinP Pisani
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne L ThomasWilliam P Steward
Mar 28, 2006·Cancer Letters·Roberta Pang, Ronnie T P Poon
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert G GishGerard T Kennealey
Sep 6, 2007·Cancer Metastasis Reviews·Richard J Epstein
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abby B SiegelJonathan D Schwartz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Nov 26, 2008·World Journal of Gastroenterology : WJG·Thomas YauRonnie-T Poon
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi
Jan 6, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Thomas YauRonnie Tung Ping Poon
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B ThomasJames Abbruzzese

❮ Previous
Next ❯

Citations

Jul 7, 2011·The Journal of Membrane Biology·Kim R Kampen
Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R A Pazo-CidP Martín-Duque
Mar 10, 2011·Nature Reviews. Clinical Oncology·Andrew X ZhuRakesh K Jain
Apr 7, 2012·Journal of Oncology·Tam DuongMathias Francois
Oct 12, 2013·World Journal of Gastroenterology : WJG·Jung Woo Shin, Young-Hwa Chung
Nov 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Austin DuffyTim F Greten
Apr 18, 2013·Contemporary Clinical Trials·Dawn Qingqing ChongHan Chong Toh
Nov 25, 2016·Frontiers in Pharmacology·Massimiliano BerrettaRaffaele Di Francia
Dec 25, 2015·Diseases·Khanh NguyenWeijing Sun
Apr 29, 2015·World Journal of Hepatology·Gan-Lu DengHong Shen
Aug 15, 2018·Journal of Clinical Medicine·Meng-Yu WuChia-Jung Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.